Diana-Sabina Vieru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana-Sabina Vieru has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bogdan Ionel Tamba
Department of Neurosurgery, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania
3 shared publications - Cristina Dobre
Institute of Psychiatry Socola, Iasi, Romania
3 shared publications - Dan Cătălin Oprea
Department of Psychiatry, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universității Str., 700115 Iasi, Romania
3 shared publications - Helene Speyer
Copenhagen Research Center for Mental Health, Copenhagen University Hospital, Copenhagen
3 shared publications - Ilinca Untu
Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
3 shared publications - Jonathan Rabinowitz
Bar-Ilan University, Ramat Gan, Israel
3 shared publications
Latest Publications
- 15 September 2026
- Published by Institutul de Pshihiatrie Socola Iasi in Bulletin of Integrative Psychiatry
- Vol. 110 (3) , 105-114
Persistence of Grandiose Delusional Content in Schizophrenia with Superimposed Vascular Dementia: A Case Report of Diagnostic and Therapeutic Impasse
Background. Patients with schizophrenia are surviving into old age in growing numbers and are at substantially elevated risk of dementia. When the two conditions coexist, clinicians face contradictory guidance: antipsychotics remain first-line for schizophrenia while carrying a mortality warning in dementia. Evidence to arbitrate between these positions is absent. Case presentation. A 74-year-old man with paranoid schizophrenia of 49 years’ duration presented with agitation and confusion following two years of progressive functional decline. Cognitive assessment yielded a Mini-Mental State Examination score of 14/30, with disproportionate loss of orientation (2/10) relative to recall (2/3). Cranial computed tomography demonstrated severe diffuse cortical atrophy with ventriculomegaly, extensive lacunar infarcts in the bilateral basal ganglia and deep white matter, and confluent periventricular and subcortical leukoaraiosis, in the context of poorly controlled hypertension, dyslipidaemia and smoking. Reversible causes were excluded. Notably, the grandiose delusional system present since the age of 25 persisted unchanged in theme, register and conviction. The patient had received trihexyphenidyl 6 mg/day continuously for decades and risperidone 6 mg/day, neither of which was reviewed. He remains permanently institutionalised. Conclusions. The thematic continuity of the delusional content across five decades distinguishes persisting primary psychosis from psychosis arising within dementia, and has direct therapeutic consequences: deprescribing algorithms developed for behavioural and psychological symptoms of dementia do not apply. Conversely, the case illustrates how an anticholinergic prescribed decades earlier for drug-induced parkinsonism may persist unexamined into a period when the parkinsonian syndrome is more plausibly vascular, at measurable cognitive cost. Systematic cognitive baselines in severe mental illness, executivesensitive screening instruments, and periodic anticholinergic review are proposed.
- 15 September 2026
- Published by Institutul de Pshihiatrie Socola Iasi in Bulletin of Integrative Psychiatry
- Vol. 110 (3) , 105-114
Persistence of Grandiose Delusional Content in Schizophrenia with Superimposed Vascular Dementia: A Case Report of Diagnostic and Therapeutic Impasse
Background. Patients with schizophrenia are surviving into old age in growing numbers and are at substantially elevated risk of dementia. When the two conditions coexist, clinicians face contradictory guidance: antipsychotics remain first-line for schizophrenia while carrying a mortality warning in dementia. Evidence to arbitrate between these positions is absent. Case presentation. A 74-year-old man with paranoid schizophrenia of 49 years’ duration presented with agitation and confusion following two years of progressive functional decline. Cognitive assessment yielded a Mini-Mental State Examination score of 14/30, with disproportionate loss of orientation (2/10) relative to recall (2/3). Cranial computed tomography demonstrated severe diffuse cortical atrophy with ventriculomegaly, extensive lacunar infarcts in the bilateral basal ganglia and deep white matter, and confluent periventricular and subcortical leukoaraiosis, in the context of poorly controlled hypertension, dyslipidaemia and smoking. Reversible causes were excluded. Notably, the grandiose delusional system present since the age of 25 persisted unchanged in theme, register and conviction. The patient had received trihexyphenidyl 6 mg/day continuously for decades and risperidone 6 mg/day, neither of which was reviewed. He remains permanently institutionalised. Conclusions. The thematic continuity of the delusional content across five decades distinguishes persisting primary psychosis from psychosis arising within dementia, and has direct therapeutic consequences: deprescribing algorithms developed for behavioural and psychological symptoms of dementia do not apply. Conversely, the case illustrates how an anticholinergic prescribed decades earlier for drug-induced parkinsonism may persist unexamined into a period when the parkinsonian syndrome is more plausibly vascular, at measurable cognitive cost. Systematic cognitive baselines in severe mental illness, executivesensitive screening instruments, and periodic anticholinergic review are proposed.
- 15 September 2026
- Published by Institutul de Pshihiatrie Socola Iasi in Bulletin of Integrative Psychiatry
- Vol. 110 (3) , 87-93
Applications of Virtual Reality in Psychiatry. Systematic Review of the Scientific Literature
Virtual reality (VR) is an increasingly investigated technology in psychiatry, with applications spanning both therapeutic and diagnostic interventions. This systematic review synthesizes evidence from systematic reviews, meta-analyses, and randomized controlled trials concerning the use of VR across major psychiatric disorders. The strongest evidence supports virtual reality exposure therapy (VRET) for anxiety disorders and specific phobias, with therapeutic effects comparable to in vivo exposure in several conditions and non-inferiority to conventional cognitive-behavioral therapy in social anxiety disorder. VR-based interventions also demonstrate beneficial effects in post-traumatic stress disorder, although their efficacy appears broadly comparable to standard treatments. In psychotic disorders, emerging evidence suggests improvements in positive and negative symptoms and cognitive functioning, including through AVATAR therapy, while evidence regarding social functioning remains limited. VR interventions may also contribute to improvements in body image, binge-eating and purging behaviors in eating disorders, and may facilitate craving assessment and cueexposure therapy in substance use disorders. Additionally, virtual environments show potential for ADHD assessment, autism-related social-skills training, and cognitive rehabilitation. Despite these promising findings, methodological limitations—including small samples, heterogeneous protocols, inadequate control groups, and limited blinding—restrict definitive conclusions. Overall, VR represents a promising adjunctive tool in psychiatry, but further high-quality research is required before widespread clinical implementation.
- 15 September 2026
- Published by Institutul de Pshihiatrie Socola Iasi in Bulletin of Integrative Psychiatry
- Vol. 110 (3) , 87-93
Applications of Virtual Reality in Psychiatry. Systematic Review of the Scientific Literature
Virtual reality (VR) is an increasingly investigated technology in psychiatry, with applications spanning both therapeutic and diagnostic interventions. This systematic review synthesizes evidence from systematic reviews, meta-analyses, and randomized controlled trials concerning the use of VR across major psychiatric disorders. The strongest evidence supports virtual reality exposure therapy (VRET) for anxiety disorders and specific phobias, with therapeutic effects comparable to in vivo exposure in several conditions and non-inferiority to conventional cognitive-behavioral therapy in social anxiety disorder. VR-based interventions also demonstrate beneficial effects in post-traumatic stress disorder, although their efficacy appears broadly comparable to standard treatments. In psychotic disorders, emerging evidence suggests improvements in positive and negative symptoms and cognitive functioning, including through AVATAR therapy, while evidence regarding social functioning remains limited. VR interventions may also contribute to improvements in body image, binge-eating and purging behaviors in eating disorders, and may facilitate craving assessment and cueexposure therapy in substance use disorders. Additionally, virtual environments show potential for ADHD assessment, autism-related social-skills training, and cognitive rehabilitation. Despite these promising findings, methodological limitations—including small samples, heterogeneous protocols, inadequate control groups, and limited blinding—restrict definitive conclusions. Overall, VR represents a promising adjunctive tool in psychiatry, but further high-quality research is required before widespread clinical implementation.
- Open Access
- 18 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e92115
Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study
Background: Negative symptoms (NS) such as anhedonia (reduced pleasure), avolition (reduced motivation), asociality (social withdrawal), blunted affect (diminished emotional expression), and alogia (poverty of speech) are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. Current medication primarily targets positive or affective symptoms, leaving NS neurobiology unaddressed. A critical research gap exists in understanding whether these symptoms share a common biological architecture across different diagnoses or whether they emerge from distinct pathological pathways. Objective: This observational, single-center study aims to characterize NS across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles and the aim of determining whether particular NS consistently occupy central positions across disorders or centrality patterns differ by diagnosis. By linking these symptom profiles to underlying neurocognitive, electrophysiological, and genetic markers, the study seeks to disentangle shared versus disorder-specific mechanisms. Methods: In total, 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Over a 4-day schedule, participants will undergo clinical (Brief Negative Symptom Scale, Positive and Negative Syndrome Scale, Hamilton Depression Rating Scale, Personal and Social Performance Scale, Udvalg for Kliniske Undersøgelser Side Effect Rating Scale, and Barnes Akathisia Rating Scale), neurocognitive (Brief Assessment of Cognition in Schizophrenia, and Temporal Experience of Pleasure Scale), and biological (resting-state electroencephalography and blood sampling for polygenic risk score) assessments. Network analysis will compute symptom centrality to determine if avolition acts as a transdiagnostic hub. Structural equation modeling will link network profiles to neurophysiological and genetic data. This methodology is designed to identify convergent biological markers, clarify avolition’s role in symptom heterogeneity, and refine understanding of NS as multidimensional phenomena beyond traditional diagnostic boundaries. Results: The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on May 8, 2024, and updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. By March 2026, the study had enrolled 286 participants. Data quality control and preliminary analyses are performed concurrently with data collection. Final statistical analyses and dissemination of results are planned following completion of the recruitment phase. Conclusions: This study will provide critical insights into the characterization and underlying mechanisms of NS across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of NS. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illnesses and related conditions.
- 18 May 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e92115
Open AccessModeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study
Background: Negative symptoms (NS) such as anhedonia (reduced pleasure), avolition (reduced motivation), asociality (social withdrawal), blunted affect (diminished emotional expression), and alogia (poverty of speech) are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. Current medication primarily targets positive or affective symptoms, leaving NS neurobiology unaddressed. A critical research gap exists in understanding whether these symptoms share a common biological architecture across different diagnoses or whether they emerge from distinct pathological pathways. Objective: This observational, single-center study aims to characterize NS across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles and the aim of determining whether particular NS consistently occupy central positions across disorders or centrality patterns differ by diagnosis. By linking these symptom profiles to underlying neurocognitive, electrophysiological, and genetic markers, the study seeks to disentangle shared versus disorder-specific mechanisms. Methods: In total, 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Over a 4-day schedule, participants will undergo clinical (Brief Negative Symptom Scale, Positive and Negative Syndrome Scale, Hamilton Depression Rating Scale, Personal and Social Performance Scale, Udvalg for Kliniske Undersøgelser Side Effect Rating Scale, and Barnes Akathisia Rating Scale), neurocognitive (Brief Assessment of Cognition in Schizophrenia, and Temporal Experience of Pleasure Scale), and biological (resting-state electroencephalography and blood sampling for polygenic risk score) assessments. Network analysis will compute symptom centrality to determine if avolition acts as a transdiagnostic hub. Structural equation modeling will link network profiles to neurophysiological and genetic data. This methodology is designed to identify convergent biological markers, clarify avolition’s role in symptom heterogeneity, and refine understanding of NS as multidimensional phenomena beyond traditional diagnostic boundaries. Results: The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on May 8, 2024, and updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. By March 2026, the study had enrolled 286 participants. Data quality control and preliminary analyses are performed concurrently with data collection. Final statistical analyses and dissemination of results are planned following completion of the recruitment phase. Conclusions: This study will provide critical insights into the characterization and underlying mechanisms of NS across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of NS. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illnesses and related conditions.
- Open Access
Modelling Negative Symptom Domains Neurobiology: Protocol for an Observational Transdiagnostic, Translational Study
Background: Negative symptoms (NS) such as anhedonia, avolition, asociality, blunted affect and alogia are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. Objective: This protocol describes the design of an observational, single-center study aimed at characterizing negative symptoms across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles. Methods: An observational study (involving no invasive procedures or drug administration other than a routine blood draw) has been designed to examine negative symptoms across psychiatric disorders. A total of 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Consenting inpatients and outpatients will complete a battery of non-invasive behavioral and cognitive assessments, undergo electroencephalogram (EEG) recording, and provide blood samples for the assessment of polygenic risk scores. Results: The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on August 5, 2024, and subsequently updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. Data quality control and preliminary analyses are performed concurrently with data collection, while final statistical analyses and dissemination of results are planned following completion of the recruitment phase. Conclusions: This study will provide critical insights into the characterization and underlying mechanisms of negative symptoms across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of negative symptoms. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illness and related conditions.
Open AccessModelling Negative Symptom Domains Neurobiology: Protocol for an Observational Transdiagnostic, Translational Study
Background: Negative symptoms (NS) such as anhedonia, avolition, asociality, blunted affect and alogia are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. Objective: This protocol describes the design of an observational, single-center study aimed at characterizing negative symptoms across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles. Methods: An observational study (involving no invasive procedures or drug administration other than a routine blood draw) has been designed to examine negative symptoms across psychiatric disorders. A total of 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Consenting inpatients and outpatients will complete a battery of non-invasive behavioral and cognitive assessments, undergo electroencephalogram (EEG) recording, and provide blood samples for the assessment of polygenic risk scores. Results: The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on August 5, 2024, and subsequently updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. Data quality control and preliminary analyses are performed concurrently with data collection, while final statistical analyses and dissemination of results are planned following completion of the recruitment phase. Conclusions: This study will provide critical insights into the characterization and underlying mechanisms of negative symptoms across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of negative symptoms. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illness and related conditions.
- Open Access
- 24 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Modelling Negative Symptom Domains Neurobiology: Protocol for an Observational Transdiagnostic, Translational Study (Preprint)
BACKGROUND Negative symptoms (NS) such as anhedonia, avolition, asociality, blunted affect and alogia are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. OBJECTIVE This protocol describes the design of an observational, single-center study aimed at characterizing negative symptoms across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles. METHODS An observational study (involving no invasive procedures or drug administration other than a routine blood draw) has been designed to examine negative symptoms across psychiatric disorders. A total of 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Consenting inpatients and outpatients will complete a battery of non-invasive behavioral and cognitive assessments, undergo electroencephalogram (EEG) recording, and provide blood samples for the assessment of polygenic risk scores. RESULTS The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on August 5, 2024, and subsequently updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. Data quality control and preliminary analyses are performed concurrently with data collection, while final statistical analyses and dissemination of results are planned following completion of the recruitment phase. CONCLUSIONS This study will provide critical insights into the characterization and underlying mechanisms of negative symptoms across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of negative symptoms. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illness and related conditions.
- 24 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessModelling Negative Symptom Domains Neurobiology: Protocol for an Observational Transdiagnostic, Translational Study (Preprint)
BACKGROUND Negative symptoms (NS) such as anhedonia, avolition, asociality, blunted affect and alogia are associated with poor functional outcomes in psychiatric and neurological disorders and are an unmet treatment need. OBJECTIVE This protocol describes the design of an observational, single-center study aimed at characterizing negative symptoms across a transdiagnostic sample of individuals with mental disorders and related conditions, with a particular focus on avolition, its biological correlates, and associated neurocognitive and electrophysiological profiles. METHODS An observational study (involving no invasive procedures or drug administration other than a routine blood draw) has been designed to examine negative symptoms across psychiatric disorders. A total of 300 participants with a primary diagnosis of schizophrenia, bipolar disorder, unipolar depressive disorder, autism, or dementia will be recruited, with a target of at least 50 individuals in each diagnostic group. Consenting inpatients and outpatients will complete a battery of non-invasive behavioral and cognitive assessments, undergo electroencephalogram (EEG) recording, and provide blood samples for the assessment of polygenic risk scores. RESULTS The initial version of the study protocol was developed in February 2024. The finalized protocol was completed on August 5, 2024, and subsequently updated on January 11, 2025, to incorporate minor methodological clarifications. Participant recruitment and data collection commenced on July 1, 2024, and are ongoing at the time of manuscript submission. Data quality control and preliminary analyses are performed concurrently with data collection, while final statistical analyses and dissemination of results are planned following completion of the recruitment phase. CONCLUSIONS This study will provide critical insights into the characterization and underlying mechanisms of negative symptoms across psychiatric disorders. By focusing on avolition, reward processing, and their interaction with neurocognitive and social cognitive deficits, it will help identify potential biological and electrophysiological markers of negative symptoms. The findings may guide the development of more precise assessment tools and inform novel therapeutic strategies, with broad translational impact for improving outcomes in individuals with serious mental illness and related conditions.
- Open Access
- 2 January 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (1) , 17-22
How the Internet influences the relationship between outpatients and gastroenterologists: A multicenter study
Background/Aims: The Internet offers a lot of non-filtered medical information which may interfere with the patient-doctor relationship. The aim of the present study was to assess the influence of the Internet on the classical doctor-patient relationship in gastroenterological outpatient settings. Materials and Methods: A multicenter study was conducted, including a representative sample selected from five major regional medical centers throughout Romania. We designed a questionnaire which had two parts. One had to be filled out by adult patients on their first visit to a gastroenterology clinic and the other by physicians, stating the diagnosis and giving a doctor-patient collaboration score. Results: From a total of 485 patients (49.9% females, mean age 50.42 years), 64.9% had Internet access, 75% out of whom searched for their symptoms online. University graduates searched for their symptoms online more often than secondary school graduates (80% vs. 31.1%, p<0.05). Most patients stated that they used the Internet to identify the most appropriate medical specialist for their condition. Internet users were less likely to visit a general practitioner (GP) before coming to a specialist (85.3% vs. 92.2%, odds ratio (OR) 0.491, 95% confidence interval (CI) 0.24-0.98, p<0.05). Patients who had searched for their symptoms online were less likely to follow the treatment prescribed by the GP (53.6% vs. 67.5%, p=0.004), but they received a better collaboration score (OR 1.12, 95% CI 1.05-1.36, p<0.05). Conclusion: The Internet exerts a positive influence on specialist doctor-patient relationship, but it might burden the health system with the incorrect tendency to replace the role of the GP. Cite this article as: Drug VL, Chirila I, Albusoda A, et al. How the Internet influences the relationship between outpatients and gastroenterologists: A multicenter study. Turk J Gastroenterol 2020; 31(1): 17-22.
- 2 January 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (1) , 17-22
Open AccessHow the Internet influences the relationship between outpatients and gastroenterologists: A multicenter study
Background/Aims: The Internet offers a lot of non-filtered medical information which may interfere with the patient-doctor relationship. The aim of the present study was to assess the influence of the Internet on the classical doctor-patient relationship in gastroenterological outpatient settings. Materials and Methods: A multicenter study was conducted, including a representative sample selected from five major regional medical centers throughout Romania. We designed a questionnaire which had two parts. One had to be filled out by adult patients on their first visit to a gastroenterology clinic and the other by physicians, stating the diagnosis and giving a doctor-patient collaboration score. Results: From a total of 485 patients (49.9% females, mean age 50.42 years), 64.9% had Internet access, 75% out of whom searched for their symptoms online. University graduates searched for their symptoms online more often than secondary school graduates (80% vs. 31.1%, p<0.05). Most patients stated that they used the Internet to identify the most appropriate medical specialist for their condition. Internet users were less likely to visit a general practitioner (GP) before coming to a specialist (85.3% vs. 92.2%, odds ratio (OR) 0.491, 95% confidence interval (CI) 0.24-0.98, p<0.05). Patients who had searched for their symptoms online were less likely to follow the treatment prescribed by the GP (53.6% vs. 67.5%, p=0.004), but they received a better collaboration score (OR 1.12, 95% CI 1.05-1.36, p<0.05). Conclusion: The Internet exerts a positive influence on specialist doctor-patient relationship, but it might burden the health system with the incorrect tendency to replace the role of the GP. Cite this article as: Drug VL, Chirila I, Albusoda A, et al. How the Internet influences the relationship between outpatients and gastroenterologists: A multicenter study. Turk J Gastroenterol 2020; 31(1): 17-22.